| Autor: |
Natalia Ruiz-Nieto, Antonio Belenguer-Benavides, Anabel Zahonero-Ferriz, Helena Benetó-Andrés, Ana Monclús-Blecua |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Neurology Perspectives, Vol 4, Iss 4, Pp 100173- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2667-0496 |
| DOI: |
10.1016/j.neurop.2024.100173 |
| Popis: |
Introduction: Guillain-Barré syndrome (GBS) is an autoimmune disease that results in demyelination and axonal damage. Although the recovery is good in most patients, 20% remain significantly disabled.Neurofilament light chain (NfL) has been established as a biomarker of axonal damage in many diseases. Methods: We measured NfL, S100B, and glial fibrillary acidic protein (GFAP) concentrations from blood and cerebrospinal fluid (CSF) taken upon admission from 19 patients with a history of GBS between January 2009 and December 2019 and investigated a correlation between them and clinical outcomes. Results: All patients fulfilled levels 1 or 2 of the Brighton diagnostic.Preceding infection was reported in 11 cases (58%).We classified 15 patients as acute inflammatory demyelinating polyneuropathy, 2 as AMAN, 1 as AMSAN, and 2 cases as Miller–Fisher syndrome.Five patients were transferred to an ICU, with a mean stay of 13 days. Functional outcome at 6 months after discharge was good in 12 patients (70.6%).We evaluated disease prognosis using the modified Erasmus GBS outcome score. The correlation was significant (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
